ClinicalTrials.gg
CompletedNCT04569487Updated Jul 31, 2024

Identification of Relevant Biological, Imaging, Mobility and Clinical Markers for Clinical Research in Sarcopenia

An interventional study of Biopsy in Sarcopenia, sponsored by Artialis. Completed at 2 sites in Belgium. Open to male participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2024-07-31.

Sponsored by Artialis · Not applicable, Interventional, and Diagnostic

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
16
Allocation
Non-randomized
Ages
65 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 30 studies in Sarcopenia with a site in Belgium — 8 open to participants now, 9 under way, none of them phase 3. Sarcopenia · Belgium.

Enrollment
13th of 16
16 · median 46
Started
2021
with 1 other
No phase
12 of 30
3 open now
Registered
16th of 30
by date
Lead sponsor
1 of 30
Artialis

Among the 30 studies in Sarcopenia with a site in Belgium, this one is the 13th largest by enrollment of the 16 interventional ones that give a count, is one of 2 that started in 2021, is one of 12 with no phase, and was the 16th registered.

Sarcopenia

1,334 studies on the registry are indexed under Sarcopenia; 418 are open to participants now.

Browse Sarcopenia studies →

Open to participants now

8 of the 30 studies in Sarcopenia with a site in Belgium are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →

Who these studies take

Of the 246 Sarcopenia studies recruiting now, 155 (63%) set no upper age limit and 32 (13%) stop at 75 or younger; 9 take children under 18; 62 take healthy volunteers.

This study: 65 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in Sarcopenia with a site in Belgium, or all of them as a file.
02

Study summary

The objective of this trial is to constitute a cohort of sarcopenic versus non-sarcopenic patients to validate the most relevant biological, imaging, mobility and clinical markers considered individually or in association for the diagnosis of sarcopenic patients.

Read the detailed description

This trial is part of a Research Program partly funded by a grant from the Walloon region entitled "Development of Markers of Sarcopenia Using an Integrated Approach : From Cell to Human".

Consistent with the above-mentioned observation, there is not only one biological marker that perfectly matches the sarcopenia criteria but there is a range of complementary biomarkers - including but not limited to inflammation markers, products of oxidative damage, serum creatinine and urinary creatinine excretion, endocrine function, urine proteomics panel, N-terminal procollagen peptides, myostatin and agrin fragment - that will together constitute the ideal panel of markers (Fougère et al, 2015). These current biomarkers and the thresholds for correlation with clinical outcomes have to be deeply evaluated in clinical trials before being considered as good biomarkers.

In addition, one research priority is to investigate and define novel biomarkers allowing an improved assessment, characterization and follow-up of elderly people with sarcopenia. Biomarkers derived from blood can indeed easily be measured in a standardized and low-cost way and are therefore very attractive.

This clinical trial aims at confirming the relevance of new soluble markers and validating the most relevant biological (previously and newly identified), imaging, mobility and clinical markers for clinical research in sarcopenia.

Newly identified soluble markers of sarcopenia coming from DEMAIN Research program and using secretomic approach (to be identified in secretome of human myotubes during the program research) using immunoassays on biological fluids.

03

Conditions studied

  • Sarcopenia

Browse trials for

04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participants will have the following inclusion criteria:

  • Male with age ≥ 65 years
  • : 20 \< BMI \< 35 kg/m2
  • Able to understand and having signed an
  • Able to follow the trial procedures

Sarcopenic population: diagnosed sarcopenia following definition of the EWGSOP2:

  • Muscle strength assessed by the handgrip test \<27 kg for male
  • Skeletal muscle mass index (Appendicular lean muscle mass) assessed by DXA \<7.0 kg/m2

Non-sarcopenic population: adapted from the EWGSOP2:

  • Muscle strength assessed by the handgrip test ≥ 27 kg
  • Skeletal muscle mass index (Appendicular lean muscle mass) assessed by DXA ≥ 7.0 kg/m2

Exclusion criteria

Exclusion Criteria:

Participants will have the following exclusion criteria:

  • Any levels of the safety parameters (Creatine Kinase (CK), (aPTT), Prothrombin Time and International Normalized Ratio (PT/INR))
  • Any severe, uncontrolled and limiting diseases (e.g. systemic inflammation, infectious diseases, active cancer, neurodegenerative disorders, diabetes) left to the investigator's discretion
  • Bed resting for more than 10 days during the 3 months preceding the recruitment
  • Immobilization of the lower limb, lasting more than one week during the 3 months preceding recruitment
  • Medical treatment with anticoagulant, insulin, , long-term (over 7.5 mg prednisone or its equivalent)
  • Severe incapacity (class IV Steinbrocker Functional Classification - Appendix 2)
  • Any treatment that may affect physical performance, muscle function, disrupts study measures or impairs the understanding of consent
  • Known acute or severe renal insufficiency ( \< 30 mL/min/1.73m2)
  • Cushing' syndrome
  • Known cachexia
  • Currently participating or having participated in another therapeutic clinical trial in the three previous months
  • Under guardianship or judicial protection
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Active comparator
    Sarcopenic population

    Diagnosed sarcopenia following definition of the EWGSOP2: * Muscle strength assessed by the handgrip test \<27 kg * Skeletal muscle mass index (Appendicular lean muscle mass) assessed by DXA \<7.0 kg/m2

    Procedure: Biopsy

  • Active comparator
    Non sarcopenic population

    Non-sarcopenic population adapted from the EWGSOP2: * Muscle strength assessed by the handgrip test ≥ 27 kg * Skeletal muscle mass index (Appendicular lean muscle mass) assessed by DXA ≥ 7.0 kg/m2

    Procedure: Biopsy

Interventions

  • ProcedureBiopsy

    Muscle biopsy from vastus lateralis (100-200 mg from non-dominant leg)

06

What researchers measure

Primary outcomes

  1. Identified soluble markers of sarcopenia

    immunoassays on biological fluids by secretomic approach

    Time frame: 3 months after biopsy

Secondary outcomes

  1. Identified imaging marker

    Appendicular lean muscle mass and adiposity (if possible) using Dual Energy Xray Absorptiometry (DXA)

    Time frame: within 15 days after Day 0 (baseline visit)

  2. Determine thePhysical performance

    Patients realize some physical tests: Short Physical Performance Battery (SPPB that are three physical tests: gait speed, balance test, chair stand test)

    Time frame: Day 0 (baseline visit)

  3. Determine the falls risk

    A global score will be calculated in function of the answers of a Self-administered questionnaire: Morse Fall Scale (MFS; falls risks for elderly)

    Time frame: Day 0 (baseline visit)

  4. Identified clinical marker

    A global score will be calculated in function of the answers of a Self-administered questionnaire: SARC-F

    Time frame: Day 0 (baseline visit)

  5. Determine the muscle strength

    Handgrip muscular strength test (upper body skeletal muscle function) using a hand dynamometer

    Time frame: Day 0 (baseline visit)

  6. Evaluate the quality of life

    A global score will be calculated in function of the answers of a Self-administered questionnaire (SF-36). The SF-36 is a 36-item patient-reported questionnaire that covers eight health domains: physical functioning (10 items), bodily pain (2 items), role limitations due to physical health problems (4 items), role limitations due to personal or emotional problems (4 items), emotional well-being (5 items), social functioning (2 items), energy/fatigue (4 items), and general health perceptions (5 items). Scores for each domain range from 0 to 100, with a higher score defining a more favorable health state.

    Time frame: Day 0 (baseline visit)

  7. Determine cognitive performance

    A global score will be calculated in function of the answers of a Self-administered questionnaire: Montreal Cognitive Assessment (MoCA)

    Time frame: Day 0 (baseline visit)

  8. Determine the nutrition status

    A global score will be calculated in function of the on Global Leadership Initiative on Malnutrition (GLIM) criteria (Cederholm et al, 2018)

    Time frame: Day 0(baseline visit)

  9. Evaluate the tolerance

    Number of Adverse events (AE or Adverse Device Effect or Device Deficiency; will be coded in terms of System Organ Class (SOC) and Low Level Terms (LLT) using the last version of MedDRA) and drop offs

    Time frame: 3 months (baseline visit to biopsy)

07

Study locations

2 sites
  • Erasme Hospital
    Brussels, 1070, Belgium
  • Universitair Ziekenhuis Brussel
    Brussel, 1090, Belgium
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2021 to primary completion in Apr 2024, 37 months.

Of 509 interventional studies with no phase under Sarcopenia, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 34. This study's 37 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 24, 2020
First posted
Sep 30, 2020
StartActual
Feb 11, 2021
Primary completionActual
Apr 2, 2024
CompletionActual
Apr 2, 2024
Last update
Jul 31, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 31, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04569487
Lead sponsor
Artialis
Responsible party
Sponsor
First posted
Sep 30, 2020
Start date
Feb 11, 2021
Primary completion
Apr 2, 2024
Completion
Apr 2, 2024
Last update
Jul 31, 2024

Study contacts

Yves Henrotin, Prof
study director · Artialis

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion